ShareRoot chairman Harvey Kaplan said: “Considering the recent change in operational and strategic leadership it is appropriate that the board undertakes a thorough review of the company’s progress to date and the current and prospective value of the assets.”
Last month, the company entered a collaboration that will see its MediaConsent platform used in a cancer clinical trial setting.
The collaboration is with Cancer Trials Australia (CTA) and the medical project is being led by The Social Science (TSS).
The MediaConsent Medical project now has three health or medical research related collaborators being St Vincent’s Hospital, Melbourne, Neuroscience Trials Australia, and CTA.
The shared goal with the MediaConsent clinical collaboration is to demonstrate how ShareRoot’s technology protects patient data and privacy whilst supporting the advancement of clinical research.